Recent research into the Guillain–Barré syndromes (GBS) has focused on anti-ganglioside
antibodies that correlate with specific clinical phenotypes. Our increasing understanding of
the role of antibodies in mediating GBS has naturally focused our attention on complement
involvement in the pathological procession. We have studied the axonal and glial
components of the murine motor nerve terminal as a model site of antibody and complement
mediated injury. Such studies are providing us with clear information on the molecular …